Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Health Care Businesses
Articles
IU incubator attracts East Coast biotech startup
Companion Diagnostics Inc. moves from Connecticut to the IU Emerging Technologies Center, hopes to create 30 high-paying jobs
by 2014.
Lilly victim of theft from Connecticut warehouse
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Health care software firm raises $1.15 million
Indianapolis-based PolicyStat LLC raised $1.15 million in angel capital from 31 individuals and Halo Capital Group.
WellPoint may be anti-competitive, Connecticut AG says
WellPoint Inc.’s Anthem Blue Cross & Blue Shield of Connecticut may constrain competition through contracts that require
that the insurer receives hospital discounts at least as favorable as any provided to a competitor.
Eli Lilly to buy European rights to Pfizer animal products
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Lilly, Transition Therapeutics make diabetes deal
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Study: Hospital clout spurs higher Calif. health costs
While insurers get the blame for rising health-care costs for consumers, surging fees from hospitals and the growing dominance
of such providers may be just as responsible for driving up expenses, according to a new study examining California's
market.
Medco profit rises as mail-order generics business grows
The pharmacy benefits manager, which has major operations in Whitestown, said fourth quarter profit rose 24 percent.
Lilly, Merck, Pfizer starting research center
Three major U.S. drugmakers said they have formed a not-for-profit company in Asia to focus on cancer research and treatments.
California regulator finds Anthem Blue Cross violations
California’s insurance regulator said Monday his office has found more than 700 violations by the state’s largest for-profit
health insurer, a subsidiary of Indianapolis-based WellPoint.
WellPoint gets tax delay in Obama health plan
Insurers WellPoint Inc. and others would get a delay in taxes on premiums and high-cost medical benefits, along with additional
funding for expanding Medicaid, under a White House proposal
Teva gets European OK to sell generic of Lilly’s Evista
Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the United States.
Pfizer’s Viagra patent partially rejected in Lilly fight
The patent on impotence drug Viagra was partially rejected after the U.S. Patent and Trademark Office said it wasn’t different
enough from a Chinese herb known as Horny Goat Weed. The patent was key to an infringement suit Pfizer filed in 2002 against
Eli Lilly and Co. over its rival Cialis drug.
Cardinal Health laying off 49 at local warehouse
Cardinal Health notified the state on Feb. 3 that it laid off 37 workers at the end of January and plans to lay off 12 more
effective April 3.
Health care venture capital swoons in Indy, holds steady statewide
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
Hill-Rom profit up 40 percent
Batesville maker of hospital equipment meets analysts’ expectations, then raises full-year profit forecast.
Indy without Lilly, the 500?
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.